Amgen (NASDAQ:AMGN) Price Target Raised to $400.00
by Renee Jackson · The Cerbat GemAmgen (NASDAQ:AMGN – Get Free Report) had its target price lifted by equities researchers at UBS Group from $390.00 to $400.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. UBS Group’s price objective would indicate a potential upside of 14.34% from the stock’s previous close.
A number of other research analysts also recently issued reports on AMGN. Daiwa Securities Group boosted their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Guggenheim upped their price objective on Amgen from $347.00 to $351.00 and gave the stock a “neutral” rating in a research note on Thursday. Rothschild & Co Redburn upped their price objective on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday, February 18th. Leerink Partners reaffirmed a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $356.24.
Check Out Our Latest Stock Analysis on AMGN
Amgen Stock Performance
Shares of NASDAQ:AMGN traded down $1.20 during mid-day trading on Monday, reaching $349.82. 2,544,880 shares of the company traded hands, compared to its average volume of 2,789,263. The company’s 50 day moving average price is $363.87 and its 200-day moving average price is $335.48. The firm has a market cap of $188.79 billion, a PE ratio of 24.58, a PEG ratio of 3.30 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen has a 52 week low of $261.43 and a 52 week high of $391.29.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts expect that Amgen will post 20.62 EPS for the current fiscal year.
Hedge Funds Weigh In On Amgen
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dogwood Wealth Management LLC boosted its stake in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC lifted its stake in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the last quarter. Board of the Pension Protection Fund bought a new stake in shares of Amgen in the 4th quarter valued at approximately $26,000. Manning & Napier Advisors LLC lifted its stake in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new stake in shares of Amgen in the 4th quarter valued at approximately $33,000. 76.50% of the stock is owned by institutional investors.
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.